The primary study intent is to examine biological mechanisms associated with acute and
chronic treatment responses in major depressive disorder (MDD). It is hypothesized that
treatment responsiveness, representing endogenous opioid system function, will be associated
with acute improvements in mood state over a 10-week treatment trial in MDD. Potential (bio)
markers of treatment effects will be tested against psychophysical responses to placebo and
active treatments.